Log In
BCIQ
Print this Print this
 

Seciera (OTX-101)

  Manage Alerts
Collapse Summary General Information
Company Auven Therapeutics Management LLLP
DescriptionNanomicellar formulation of cyclosporine
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase III
Standard IndicationDry eye
Indication DetailsTreat dry eye disease
Regulatory Designation
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

1

$40.0M

$40.0M

0


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone

10/26/2016

$40.0M

$40.0M

Undisclosed

Get a free BioCentury trial today